Acquired Immunodeficiency Syndrome Clinical Trial
Official title:
Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation
HIV virus is an etiologic agent of ( AIDS ) immunodeficiency syndrome . It is known that the estimated rate of transfer from mother to baby is 25% to 45%, pregnancy rate is 5-10%, pregnancy rate is 15-20% and in lactation period is 5-10%. Risk factors; maternal viral load, breastfeeding, vaginal birth, and prematurity. Although there is a high rate of false positivity in prenatal screening in our country, one of the factors affecting this is the number of pregnancies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 | |
| Completed |
NCT02929069 -
A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
|
N/A | |
| Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
| Completed |
NCT02583464 -
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
|
Phase 1 | |
| Completed |
NCT02264509 -
Peripheral Arterial Insufficiency Associated With HIV/AIDS
|
N/A | |
| Completed |
NCT01440569 -
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
|
Phase 3 | |
| Completed |
NCT00551330 -
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
| Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
| Completed |
NCT00001409 -
Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications
|
Phase 1 | |
| Completed |
NCT00000590 -
Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
|
Phase 3 | |
| Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
| Completed |
NCT00005273 -
Pulmonary Complications of HIV Infection Study (PACS)
|
N/A | |
| Completed |
NCT00005303 -
Effectiveness of AIDS Antibody Screening
|
N/A | |
| Completed |
NCT00005301 -
Transfusion Safety Study (TSS)
|
N/A | |
| Completed |
NCT00001650 -
Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
|
N/A | |
| Withdrawn |
NCT00243568 -
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
|
Phase 3 | |
| Recruiting |
NCT05031819 -
Managing Hypertension Among People Living With HIV
|
N/A | |
| Completed |
NCT00394004 -
Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials
|
N/A | |
| Completed |
NCT01967940 -
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
|
Phase 3 |